Rapport Therapeutics (RAPP) Accumulated Depreciation (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Accumulated Depreciation data on file, last reported at $1.9 million in Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $1.9 million, up 59.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 59.5% YoY), and the FY2025 annual result was $2.0 million, up 105.39% from the prior year.
• Accumulated Depreciation fell to $1.9 million in Q1 2026 per RAPP's latest filing, from $2.0 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $2.0 million in Q4 2025 and troughed at $127000.0 in Q4 2023.
• A 4-year average of $1.2 million and a median of $1.2 million in 2025 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2024 and 2026: Accumulated Depreciation jumped 659.84% in 2024, then jumped 59.5% in 2026.
• A 4-year view of Accumulated Depreciation shows it stood at $127000.0 in 2023, then jumped by 659.84% to $965000.0 in 2024, then surged by 105.39% to $2.0 million in 2025, then fell by 2.62% to $1.9 million in 2026.
• Business Quant data shows RAPP's Accumulated Depreciation at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.